Jefferies analyst Peter Welford maintained a Hold rating on Roche Holding AG (RHHVF) on June 8 and set a price target of CHF330.00. The company’s shares closed last Wednesday at $378.82, close to its 52-week high of $379.43.
According to TipRanks.com, Welford is a 5-star analyst with an average return of 19.2% and a 67.2% success rate. Welford covers the Healthcare sector, focusing on stocks such as Vaccitech Plc Sponsored ADR, AstraZeneca, and Qiagen.
Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $387.41, a 3.7% upside from current levels. In a report issued on June 2, Societe Generale also downgraded the stock to Hold with a CHF340.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $379.43 and a one-year low of $308.57. Currently, Roche Holding AG has an average volume of 7,031.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
